(19)
(11) EP 2 137 216 A2

(12)

(88) Date of publication A3:
31.12.2008

(43) Date of publication:
30.12.2009 Bulletin 2009/53

(21) Application number: 08726797.7

(22) Date of filing: 12.03.2008
(51) International Patent Classification (IPC): 
C07K 16/28(2006.01)
A61K 39/395(2006.01)
C07K 16/00(2006.01)
C12N 15/11(2006.01)
A61P 35/00(2006.01)
(86) International application number:
PCT/US2008/003355
(87) International publication number:
WO 2008/112290 (18.09.2008 Gazette 2008/38)
(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR
Designated Extension States:
AL BA MK RS

(30) Priority: 12.03.2007 US 906764 P
12.03.2007 US 906727 P

(71) Applicants:
  • Vasgene Therapeutics, Inc.
    Sharon Hill, PA 19079 (US)
  • Board of Regents of the University of Texas System
    Austin, TX 78701 (US)

(72) Inventors:
  • KRASNOPEROV, Valery
    South Pasadena, CA 91030 (US)
  • GILL, Parkash
    Agoura Hills, CA 91301 (US)
  • SOOD, Anil, K.
    Pearland, TX 77584 (US)

(74) Representative: Lee, Nicholas John et al
Kilburn & Strode LLP 20 Red Lion Street
London WC1R 4PJ
London WC1R 4PJ (GB)

   


(54) USE OF EPHB4 AS A DIAGNOSTIC MARKER AND A THERAPEUTIC TARGET FOR OVARIAN CANCER